Quarterly Report · 10-Q
Lexaria Bioscience Corp.
LEXXNASDAQEQUITYCurrent
Quarterly Report
Company context
Lexaria is a biotechnology company dedicated to the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“APIs”) using our patented DehydraTECHTM drug delivery technology. DehydraTECH combines APIs with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods.
Current securities
Historical securities (1)
Recent company filings
- D filingSep 21, 2026
- Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD DisclosureSep 9, 2026
- Other EventsSep 1, 2026
- Other EventsAug 17, 2026
- Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingAug 10, 2026
As-filed source
As filedOpen full document ↗